This medicine is now known as velmanase alfa.
On 26 January 2005, orphan designation (EU/3/04/260) was granted by the European Commission to Zymenex A/S, Denmark, for recombinant human α-mannosidase for the treatment of α-mannosidosis.
The sponsorship was transferred to Chiesi Farmaceutici S.p.A., Italy, in January 2015.
Recombinant human α-mannosidase has been authorised in the EU as Lamzede since 23 March 2018.
Recombinant human alpha-Mannosidase (velmanase alfa)
|Disease / condition||
Treatment of alpha-mannosidosis
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.